THE Therapeutic Goods Administration has published an Australian Public Assessment Report for new chemical entity Biogen's Spinraza (nusinersen), indicated for treatment of 5q Spinal Muscular Atrophy - tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 31 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Aug 18